Pacira Pharmaceuticals(PCRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PCRX Pacira Pharmaceuticals

Post-Mkt 03-13 18:58:10 EDT

23.26

-0.27

-1.15%

盘后23.26

+0.000.00%

17:25 EDT

High23.65	Low23.04	Vol798.80K
Open23.30	D1 Closing23.53	Amplitude2.61%
Mkt Cap941.79M	Tradable Cap858.20M	Total Shares40.49M
T/O18.56M	T/O Rate2.17%	Tradable Shares36.90M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PCRX","market":"US","secType":"STK","nameCN":"Pacira Pharmaceuticals","latestPrice":23.26,"timestamp":1773432000000,"preClose":23.53,"halted":0,"volume":798804,"hourTrading":{"tag":"盘后","latestPrice":23.26,"preClose":23.26,"latestTime":"17:25 EDT","volume":29402,"amount":683890.196578,"timestamp":1773437118460,"change":0,"changeRate":0,"amplitude":0.006879},"delay":0,"changeRate":-0.011474713132171677,"floatShares":36895900,"shares":40489894,"eps":0.157833,"marketStatus":"Post-Mkt","change":-0.27,"latestTime":"03-13 18:58:10 EDT","open":23.3,"high":23.65,"low":23.035,"amount":18563834.314944,"amplitude":0.026137,"askPrice":23.26,"askSize":100,"bidPrice":22.81,"bidSize":87,"shortable":3,"etf":0,"ttmEps":0.157833,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1773446400000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1296709200000,"exchange":"NASDAQ","adjPreClose":23.53,"preHourTrading":{"tag":"盘前","latestPrice":23.34,"preClose":23.53,"latestTime":"09:29 EDT","volume":4433,"amount":104520.897195,"timestamp":1773408599999,"change":-0.19,"changeRate":-0.008075,"amplitude":0.141521},"postHourTrading":{"tag":"盘后","latestPrice":23.26,"preClose":23.26,"latestTime":"17:25 EDT","volume":29402,"amount":683890.196578,"timestamp":1773437118460,"change":0,"changeRate":0,"amplitude":0.006879},"volumeRatio":1.230676,"impliedVol":0.3361,"impliedVolPercentile":0.1116},"requestUrl":"/m/hq/s/PCRX","defaultTab":"news","newsList":[{"id":"2619777158","title":"BUZZ-U.S. STOCKS ON THE MOVE  -Natera, Pacira BioSciences, Kezar Life Sciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2619777158","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619777158?lang=en_us&edition=fundamental","pubTime":"2026-03-12 23:59","pubTimestamp":1773331150,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE  -Natera, Pacira BioSciences, Kezar Life SciencesWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning Ne","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nL6N40014H:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765646.SGD","KMLI","CE","XOMX","TBBK","RPID","MUR","AAL","CF","DG","DAL","BMBL","LU1116320737.USD","BBW","OWL","AALG","SG9999014898.SGD","CASH","SG9999014906.USD","ARES","WLTH","CUBI","NTRA","PCRX","XOMO","LU0175139822.USD","IE0002270589.USD","INTS","GYRE","LU1868837565.USD","NOG","SPRC","UAL","DOW","GFS","MOS","JBL","MELI","BX","DKS","KKR","XOMZ","BK4121","LUV","SM","GIII","KZR"],"gpt_icon":1},{"id":"2618313469","title":"Doma Perpetual: Asserts Frank Lee Should Be Replaced Immediately; Pacira Biosciences Board Should Name Interim CEO & Conduct Formal Sale Process","url":"https://stock-news.laohu8.com/highlight/detail?id=2618313469","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618313469?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:20","pubTimestamp":1773318000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nTUA6XQ6NC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PCRX","BK4007"],"gpt_icon":0},{"id":"2618597999","title":"Pacira BioSciences to Review Activist Investor's Proposed Board Nominees","url":"https://stock-news.laohu8.com/highlight/detail?id=2618597999","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618597999?lang=en_us&edition=fundamental","pubTime":"2026-03-12 05:43","pubTimestamp":1773265380,"startTime":"0","endTime":"0","summary":"Pacira BioSciences said its board would review the nominees proposed by activist investor Doma Perpetual Capital Management.Pacira confirmed Wednesday that Doma nominated three director candidates to stand for election to its board at its annual meeting of shareholders.Doma had said earlier Wednesday its nominees include Christopher Dennis, a physician executive and board-certified psychiatrist; Oliver Benton Curtis III, a former federal prosecutor and trial lawyer; and Eric de Armas, Doma's finance chief and chief compliance officer.Pacira said it has met with Doma 12 times since Frank Lee became its chief executive officer in 2024. It said Doma has not provided new insights regarding Pacira's strategy that it has not already evaluated or executed.Doma said Pacira has underserved its shareholders by raising management compensation and recording higher expenses as the stock has declined. Doma also called for the replacement of Pacira's CEO.Pacira said its plans have the backing of its ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCRX","BK4007"],"gpt_icon":0},{"id":"2618922534","title":"BUZZ-Pacira rises as DOMA pushes for CEO ouster, board shake-up and sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2618922534","media":"Reuters","labels":["executive","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618922534?lang=en_us&edition=fundamental","pubTime":"2026-03-12 01:19","pubTimestamp":1773249559,"startTime":"0","endTime":"0","summary":"BUZZ-Pacira rises as DOMA pushes for CEO ouster, board shake-up and sale** Shares of drugmaker Pacira BioSciences PCRX.O rise 2% to $22.78 premarket** Activist investor DOMA Perpetual says it has nominated three directors to PCRX board and is seeking the removal of CEO Frank Lee, citing years of poor financial performance** Says Pacira’s stock has fallen 56% over 10 years, 68% over five years and 30% during Lee’s tenure** Adds Pacira is too small to effectively market its non-opioid surgery pain drug Exparel and urges a formal sale process** Criticizes PCRX board for approving high executive pay and moving headquarters to San Francisco** Shares rose ~37% in 2025","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nL4N3ZZ1U7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PCRX","BK1191","00950"],"gpt_icon":0},{"id":"2618922600","title":"Doma Perpetual nominates three to Pacira board","url":"https://stock-news.laohu8.com/highlight/detail?id=2618922600","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618922600?lang=en_us&edition=fundamental","pubTime":"2026-03-12 01:10","pubTimestamp":1773249023,"startTime":"0","endTime":"0","summary":"Doma Perpetual Capital Management, which owns 7.1% of Pacira’s (PCRX) outstanding shares, announced its nomination of three director candidates to ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/doma-perpetual-nominates-three-to-pacira-board-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/doma-perpetual-nominates-three-to-pacira-board-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","PCRX"],"gpt_icon":0},{"id":"2618924799","title":"DOMA Perpetual nominates three directors for Pacira board after taking 7.1% stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2618924799","media":"Reuters","labels":["executive","shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618924799?lang=en_us&edition=fundamental","pubTime":"2026-03-12 01:07","pubTimestamp":1773248825,"startTime":"0","endTime":"0","summary":"DOMA Perpetual, which said it owns about 7.1% of Pacira’s common shares, nominated three director candidates for the board: Christopher Dennis, Oliver Benton Curtis and Eric de Armas. DOMA said the stock is down 56% over the last decade and down 68% over the last five years. It also called for CEO Frank Lee to be replaced and for the board to name an interim CEO. DOMA urged the board to engage bankers and run a sale process for the company.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL7Mh15M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"DOMA Perpetual nominates three directors for Pacira board after taking 7.1% stake","news_tag":"executive,shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PCRX"],"gpt_icon":0},{"id":"2618924768","title":"Doma Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira Biosciences, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2618924768","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618924768?lang=en_us&edition=fundamental","pubTime":"2026-03-12 01:06","pubTimestamp":1773248804,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nTUA2PHC4Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PCRX"],"gpt_icon":0},{"id":"2618247759","title":"Doma Perpetual Capital Management: Believes Board Must Avoid Taking Any Further Risk With Ip Battles","url":"https://stock-news.laohu8.com/highlight/detail?id=2618247759","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618247759?lang=en_us&edition=fundamental","pubTime":"2026-03-12 01:06","pubTimestamp":1773248804,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nTUA2PHC4Q:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PCRX","BK4007"],"gpt_icon":0},{"id":"2618041924","title":"Doma Perpetual Capital Management- Calls for Immediate Replacement of CEO Frank Lee and Conduct Formal Sale Process","url":"https://stock-news.laohu8.com/highlight/detail?id=2618041924","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618041924?lang=en_us&edition=fundamental","pubTime":"2026-03-12 01:06","pubTimestamp":1773248804,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nTUA2PHC4Q:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PCRX","BK4007"],"gpt_icon":0},{"id":"2617680716","title":"BRIEF-Pacira Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2617680716","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617680716?lang=en_us&edition=fundamental","pubTime":"2026-03-06 21:03","pubTimestamp":1772802214,"startTime":"0","endTime":"0","summary":"BRIEF-Pacira Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)March 6 (Reuters) - Pacira Biosciences Inc PCRX.O:PACIRA BIOSCIENCES REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nTUA4X5FVJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCRX","BK4007"],"gpt_icon":0},{"id":"2617680292","title":"Pacira BioSciences Reports Inducement Equity Grants to New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2617680292","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617680292?lang=en_us&edition=fundamental","pubTime":"2026-03-06 21:01","pubTimestamp":1772802097,"startTime":"0","endTime":"0","summary":"Pacira BioSciences granted inducement equity awards on March 3, 2026 to three new employees under its Amended and Restated 2014 Inducement Plan. One employee received stock options covering 2,400 shares with a 10-year term, a four-year vesting schedule, and an exercise price of $22.10 per share. Three employees received restricted stock units totaling 5,500 shares that vest annually in four equal installments starting March 1, 2027, with vesting dependent on continued employment.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nNDL1bkj7H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","SG9999014013.SGD","PCRX","LU0314104364.USD","LU2095319765.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU2210149790.SGD","LU2210150020.SGD","SG9999014005.SGD","SG9999014039.USD","IE00BGHQF748.EUR","BK4585","IE00BKPKM429.USD","SG9999014021.USD","BK4007","NDAQ","BK4112"],"gpt_icon":0},{"id":"2616941558","title":"Pacira BioSciences to Join Analyst-Led Fireside Chat at Barclays Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2616941558","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616941558?lang=en_us&edition=fundamental","pubTime":"2026-03-04 21:02","pubTimestamp":1772629367,"startTime":"0","endTime":"0","summary":"Pacira BioSciences to Join Analyst-Led Fireside Chat at Barclays Global Healthcare Conference               Pacira BioSciences will take part in an analyst-led fireside chat at the Barclays 28th Annua","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDLbNQwhg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0345770993.USD","PCRX","BARC.UK","IE00B3QW5Z07.USD","LU1668664300.SGD","BK4112","LU2095319765.USD","BK5152","LU1035777561.USD","LU0048578792.EUR","LU0047473722.EUR","LU1078025761.USD","LU0345777147.USD","LU1023061473.USD","LU0987226296.USD","LU0106831901.USD","BAI","SG9999014005.SGD","LU0997586606.USD","BK4588","LU0161305163.EUR","LU0345770308.USD","BK4585","LU0964806797.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU0047473722.SGD","LU1791807156.HKD","LU0314104364.USD","SG9999014013.SGD","LU0345777659.USD","LU2646069778.SGD","LU0171281750.USD","NDAQ","SG9999014039.USD","BK4007","IE00B64PRP62.GBP","LU2210149790.SGD","LU0550127509.SGD","LU1064927863.SGD","SG9999014021.USD","LU2210150020.SGD","LU1023061713.HKD"],"gpt_icon":0},{"id":"2616396208","title":"Analysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (PCRX) and Harrow Health (HROW)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616396208","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616396208?lang=en_us&edition=fundamental","pubTime":"2026-03-03 09:50","pubTimestamp":1772502619,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Pacira Pharmaceuticals (PCRX – Research Report) an...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-pacira-pharmaceuticals-pcrx-and-harrow-health-hrow-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-pacira-pharmaceuticals-pcrx-and-harrow-health-hrow-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","LU0029874061.USD","HROW","BK4007","BK4557","PCRX","BK4585","HCSG","XBI","XLV","BK4588","LU0128526141.USD","BK4581","LABU"],"gpt_icon":0},{"id":"2616799332","title":"Pacira Presents IGOR Real-World Studies Highlighting EXPAREL and iovera Knee Pain Benefits at AAOS 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2616799332","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616799332?lang=en_us&edition=fundamental","pubTime":"2026-03-02 21:02","pubTimestamp":1772456579,"startTime":"0","endTime":"0","summary":"Pacira BioSciences reported real-world evidence from its Innovations in Genicular Outcomes Registry , including two observational studies in knee osteoarthritis and total knee arthroplasty patients. One study found that EXPAREL  was associated with lower pain scores, reduced opioid use, improved function, and shorter length of stay versus conventional local anesthetics after primary unilateral total knee arthroplasty, with follow-up through three months. A second study reported that iovera cryoneurolysis was associated with reductions in pain and improved function for up to 12 months in patients with knee osteoarthritis. Results from both studies were presented at the American Academy of Orthopedic Surgeons 2026 Annual Meeting.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDL7WK5ws:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4588","BK4112","NDAQ","SG9999014039.USD","IE00B3QW5Z07.USD","SG9999014005.SGD","SG9999014021.USD","BK4585","BK4007","IE00BGHQF748.EUR","LU0314104364.USD","LU2095319765.USD","LU2210149790.SGD","LU2210150020.SGD","SG9999014013.SGD","PCRX"],"gpt_icon":0},{"id":"2616820833","title":"Pacira BioSciences (PCRX) Valuation Check After Mixed Share Performance And High P/E Multiple","url":"https://stock-news.laohu8.com/highlight/detail?id=2616820833","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616820833?lang=en_us&edition=fundamental","pubTime":"2026-03-01 21:16","pubTimestamp":1772370967,"startTime":"0","endTime":"0","summary":"Why Pacira BioSciences is on investors’ radar today\nPacira BioSciences (PCRX) has been drawing attention after a mixed share price pattern, with a 6.7% gain over the past month contrasting with negative returns over the past 3 months and year to date.\nSee our latest analysis for Pacira BioSciences.\nAt the current share price of $21.91, Pacira BioSciences shows a mixed picture, with a 6.7% 30 day share price return set against a 10.4% year to date share price decline and a 68.3% five year...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcrx/pacira-biosciences/news/pacira-biosciences-pcrx-valuation-check-after-mixed-share-pe","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcrx/pacira-biosciences/news/pacira-biosciences-pcrx-valuation-check-after-mixed-share-pe","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PCRX","BK4007"],"gpt_icon":0},{"id":"2614854186","title":"Truist Adjusts Price Target on Pacira Biosciences to $27 From $28, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2614854186","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614854186?lang=en_us&edition=fundamental","pubTime":"2026-02-27 22:24","pubTimestamp":1772202261,"startTime":"0","endTime":"0","summary":"Pacira Biosciences (PCRX) has an average rating of overweight and mean price target of $29.57, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PCRX","BK4007"],"gpt_icon":0},{"id":"2614855470","title":"Truist Financial Reaffirms Their Buy Rating on Pacira Pharmaceuticals (PCRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614855470","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614855470?lang=en_us&edition=fundamental","pubTime":"2026-02-27 20:56","pubTimestamp":1772197015,"startTime":"0","endTime":"0","summary":"Truist Financial analyst Les Sulewski maintained a Buy rating on Pacira Pharmaceuticals today and set a price target of $27.00. According to TipRan...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/truist-financial-reaffirms-their-buy-rating-on-pacira-pharmaceuticals-pcrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/truist-financial-reaffirms-their-buy-rating-on-pacira-pharmaceuticals-pcrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PCRX"],"gpt_icon":0},{"id":"2614107051","title":"BRIEF-Pacira Biosciences Reports Fourth Quarter And Full-Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2614107051","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614107051?lang=en_us&edition=fundamental","pubTime":"2026-02-27 07:20","pubTimestamp":1772148026,"startTime":"0","endTime":"0","summary":"BRIEF-Pacira Biosciences Reports Fourth Quarter And Full-Year 2025 Financial ResultsFeb 27 (Reuters) - Pacira Biosciences Inc PCRX.O:PACIRA BIOSCIENCES REPORTS FOURTH QUARTER AND FULL-YEAR 2025 FINANC","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nTUABW2MKL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PCRX"],"gpt_icon":0},{"id":"2614507541","title":"Pacira BioSciences Q4 Adj. EPS $0.57 Misses $0.90 Estimate, Sales $196.873M Miss $200.424M Estimate.","url":"https://stock-news.laohu8.com/highlight/detail?id=2614507541","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614507541?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:05","pubTimestamp":1772139901,"startTime":"0","endTime":"0","summary":"Pacira BioSciences (NASDAQ:PCRX) reported quarterly earnings of $0.57 per share which missed the analyst consensus estimate of $0.90 by 36.95 percent. This is a 37.36 percent decrease over earnings of $0.91 per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/02/50908986/pacira-biosciences-q4-adj-eps-0-57-misses-0-90-estimate-sales-196-873m-miss-200-424m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Pacira BioSciences Q4 Adj. EPS $0.57 Misses $0.90 Estimate, Sales $196.873M Miss $200.424M Estimate.","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCRX","BK4007"],"gpt_icon":0},{"id":"2614756150","title":"BRIEF-Pacira Biosciences FY Adjusted EBITDA USD 186.5 Million Vs. IBES Estimate USD 204 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614756150","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614756150?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:01","pubTimestamp":1772139706,"startTime":"0","endTime":"0","summary":"BRIEF-Pacira Biosciences FY Adjusted EBITDA USD 186.5 Million Vs. IBES Estimate USD 204 Million\n\n\nFeb 26 (Reuters) - Pacira Biosciences FY net income USD 7 million.\n\nFY adjusted net income USD 122.3 million vs. IBES estimate USD 139.8 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nPLX0D9001:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCRX","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pacira.com","stockEarnings":[{"period":"1week","weight":0.0293},{"period":"1month","weight":0.1078},{"period":"3month","weight":-0.105},{"period":"6month","weight":-0.1324},{"period":"1year","weight":0.0676},{"period":"ytd","weight":-0.0908}],"compareEarnings":[{"period":"1week","weight":-0.0224},{"period":"1month","weight":-0.0377},{"period":"3month","weight":-0.023},{"period":"6month","weight":0.0132},{"period":"1year","weight":0.1918},{"period":"ytd","weight":-0.0233}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.04958},{"month":2,"riseRate":0.666667,"avgChangeRate":0.024537},{"month":3,"riseRate":0.5,"avgChangeRate":-0.000127},{"month":4,"riseRate":0.6,"avgChangeRate":0.040098},{"month":5,"riseRate":0.533333,"avgChangeRate":0.021597},{"month":6,"riseRate":0.4,"avgChangeRate":0.013306},{"month":7,"riseRate":0.4,"avgChangeRate":-0.031855},{"month":8,"riseRate":0.533333,"avgChangeRate":0.016779},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.011519},{"month":10,"riseRate":0.266667,"avgChangeRate":-0.02773},{"month":11,"riseRate":0.733333,"avgChangeRate":0.066003},{"month":12,"riseRate":0.6,"avgChangeRate":0.042036}],"exchange":"NASDAQ","name":"Pacira Pharmaceuticals","nameEN":"Pacira Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Pacira Pharmaceuticals(PCRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Pacira Pharmaceuticals(PCRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Pacira Pharmaceuticals,PCRX,Pacira Pharmaceuticals股票,Pacira Pharmaceuticals股票老虎,Pacira Pharmaceuticals股票老虎国际,Pacira Pharmaceuticals行情,Pacira Pharmaceuticals股票行情,Pacira Pharmaceuticals股价,Pacira Pharmaceuticals股市,Pacira Pharmaceuticals股票价格,Pacira Pharmaceuticals股票交易,Pacira Pharmaceuticals股票购买,Pacira Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Pacira Pharmaceuticals(PCRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Pacira Pharmaceuticals(PCRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}